1Kalina A, Csaszar A, Fust G, et al. The association of serum lipoprotein(a) levels, apolipoprotein(a) size and (TTTTA)(n) polymorphism with coronary heart disease. Clin Chim Acta, 2001, 309(1): 45-51.
2Gonbert S, Saint-Jore B, Giral P, et al. Molecular analysis of apo(a) fragmentation in polygenic hypercholesterolemia: characterization of a new plasma fragment pattern. Arterioscler Thromb Vasc Biol, 2001, 21(8): 1353-1358.
3Yazici M, Demircan S, Durna K, et al. Lipoprotein(a) levels in patients with unstable angina and their relationship with atherothrombosis and myocardial damage. Int J Clin Pract, 2005, 59(2):150-155.
4Schneider M, Witztum JL, Young SG, et al. High-level lipoprotein[a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J Lipid Res, 2005, 46(4):769-778.
5Devlin CM, Lee SJ, Kuriakose G, et al, An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler Thromb Vasc Biol, 2005, 25(8):1704-1710.
6Tsironis LD, Katsouras CS, Lourida ES, et al. Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis, 2004, 177(1): 193-201.
7Buechler C, Ullrich H, Ritter M, et al. Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood, 2001, 97(4): 981-986.
8Seed M, Ayres KL, Humphries SE, et al. Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. Am J Med,2001, 110(1): 22-27.
9von-Eckardstein A, Schulte H, Cullen P, et al. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol, 2001, 37(2): 434-439.
10Bilgen D, Sonmez H, Ekmekei H, et al. The relationship of TFPI,Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease. Clin Biochem, 2005, 38(1): 92-96.
